All In Biotech

Drug Trial Radar · NCT07560449

QLS4131 Combination Therapy in Malignant Plasma Cell Neoplasms

A Multicenter, Open-Label Phase II Study to Evaluate QLS4131 Combination Therapy in the Treatment of Malignant Plasma Cell Neoplasms

Last checked: Nov 19, 2026Latest source record: May 1, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Not yet recruiting

Status

Not yet recruiting

Enrollment

162

Planned (sponsor's estimate)

Start

Jun 2026

Primary completion

Jun 2028

Study completion Jun 2030

Sponsor

Lead sponsor
Qilu Pharmaceutical Co., Ltd.Industry
Sponsor type
Industry
First posted
May 1, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Non randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of the study is to compare the efficacy of QLS4131(SC) in combination with QL2109, with or without pomalidomide or lenalidomide, and QLS4131 (SC) in combination with QL2109, and QLS4131 (SC) in combination with Pomalidomide, and QLS4131(SC) in combination with QL2109 and Lenalidomide.

Conditions

  • Malignant Plasma Cell Neoplasms

Interventions

  • QLS4131Drug

    QLS4131 will be administered subcutaneously.

  • QL2109Drug

    QL2109 will be administered subcutaneously.

  • PomalidomideDrug

    Pomalidomide will be self-administered as a single dose orally.

  • LenalidomideDrug

    Lenalidomide will be self-administered as a single dose orally.

  • DexamethasoneDrug

    Dexamethasone will be administered orally or intravenously.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. DLTTime frame: From time of the first dose of QLS4131 to end of DLT period (28 days)
  2. MTDTime frame: Up to 2 years
  3. ORR (Partial Response [PR] or Better)Time frame: Up to 2 years
  4. Overall Minimal Residual Disease (MRD)Time frame: Up to 2 years

Locations

No sites are listed on the registry yet.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.